Hodgkins Lymphoma Cancer Studies Currently Recruiting Participants at the University of Chicago Comprehensive Cancer Center

Study Number Title
12377A Lymphoma Program Clinical Research Screening Protocol
10-064-B Molecular characterization of hematopoietic malignancies
Select
10-406-A CALGB 50801: Phase II Trial of Response-Adapted Therapy based on Positron Emission Tomography (PET) for Bulky Stage I and Stage II Classical Hodgkin Lymphoma (HL)
10-558-B Long Term Database Collection for Lymphoma
11-0468 Phase II Study of Lenalidomide plus Rituximab in Patients with Previously Untreated Mantle Cell Lymphoma
11-0601 Outcomes of Patients with Newly Diagnosed Peripheral T-cell Lymphoma Treated with Aggressive Chemotherapy
12-1087 Comparison of Methylation Patterns By Age In Patients With Diffuse Large B-cell Lymphoma (DLBCL) and Follicular Lymphoma (FL)
IRB13-0593 Clinical Outcomes In Patients with Diffuse Large B Cell Lymphoma Harboring Mutations In c-MYC, BCL2, and BCL6 Treated With and Without a Consolidative Stem Cell Transplant
Select
13-0119 CALGB 51101: A Randomized Phase II Trial of Myeloablative Versus Non-Myeloablative Consolidation Chemotherapy For Newly Dianosed Primary CNS B-Cell Lymphoma
Select
IRB13-0510 A051202: A Phase I Trial of Lenalidomide, Rituximab, and Idelalisib in Recurrent Follicular Lymphoma
Select
IRB13-0570 A051103: A Phase I Study of Rituximab, Lenalidomide, and Ibrutinib in Previously Untreated Follicular Lymphoma
Select
IRB13-0571 A051201: A Phase I/Randomized Phase II Trial of Idelalisib, Lenalidomide, and Rituximab in Patients with Relapsed/Refractory Mantle Cell Lymphoma
IRB14-0081 Phase I, Multicenter, Cohort Dose Escalation Trial to Determine the Safety, Tolerance, and Maximum Tolerated Dose of DCR-MYC, a Lipid Nanoparticle (LNP)-Formulated Small Inhibitory RNA (siRNA) Oligonucleotide Targeting MYC, in Patients with Refractory Locally Advanced or Metastatic Solid Tumor Malignancies, Multiple Myeloma, or Lymphoma
IRB13-1105 NCI 9426: A Phase I Study of Ibrutinib (PCI-32765) in Combination with Lenalidomide in Relapsed and Refractory B-Cell Non-Hodgkin's Lymphoma

To learn more about cancer clinical trials or to make an appointment, call toll-free 1-855-702-8222 (adult trials) or 1-773-702-6808 (pediatric trials). Although our objective is to provide an updated listing of clinical trials, please note that a listing here does not guarantee that a trial is open or available to any specific patient. Additional trials may be available that are not listed. Complete information is available only from a treating physician.